Deciphera Pharmaceuticals deciphera.com


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. Its small molecule drug candidates are directed against an important family of enzymes called kinases, known to be directly involved in the growth and spread of many cancers. The company uses their deep understanding of kinase biology together with a p...Show all

Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on improving the lives of cancer patients by tackling key mechanisms of drug resistance that limit the rate and/or durability of response to existing cancer therapies. It...Show all

Company (IPO / Went public)

Phone: 781-209-6400

Fax:

500 Totten Pond Rd
6th Floor
Waltham, 02451
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Deciphera Pharmaceuticals $271.1M Sep 28, 2017
See all 23 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Deciphera Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 7 investors

Competitors

Company Status Description Investors

Vitae Pharmaceuticals

Fort Washington, Pennsylvania, United States
AcquiredVitae Pharmaceuticals is a clinical stage biopharmaceutical company discovering and developing a portfolio of small molecule compounds that address disease areas, including: chronic kidney disease, diabetes, Alzheimer's disease and atherosclerosis. Vitae's lead compound, VTP-27999, is a potent and selective renin inhibitor offering the potential for superior renal protection in patients suffering from chronic kidney disease. Vitae's discovery platform has advantages in creating and analyzing dru...Show allLogin to see details

Entomed, S.A.

Tewksbury, Massachusetts, United States
Alive / ActiveEntomed designs and develops antibiotics derived from insects.Login to see details
See all 23 competitors